Saturday, December 3, 2022


Biotechnology News Magazine

NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, today announced that enrollment has commenced in two large, multicenter double-blind trials of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD).

The first trial, known as ADHD-GEMS and sponsored by the National Institutes of Mental Health (NIMH), is being conducted at UCLA and Seattle Children’s Hospital. Up to 225 children will be enrolled in a 4-week double-blinded phase followed by up to 1-year of open label follow-up.

The second trial, known as the ATTENS project, is sponsored by the UK’s National Institute for Health Research and is being conducted at King’s College London and the University of Southampton. This trial will enroll up 150 children and adolescents with ADHD for a 4-week blinded period and will obtain fMRI data in approximately 50 subjects to better understand the underlying eTNS mechanism of action.

“The start of enrollment in these two trials marks a major milestone for NeuroSigma and for advancing alternatives to medications to treat ADHD,” said Ian Cook, M.D., NeuroSigma’s Chief Medical Officer. “The data generated will significantly expand the evidence base for eTNS as a treatment for pediatric ADHD and, we believe, demonstrate the value of eTNS as a non-pharmaceutical alternative for treating this common condition. We are also excited to examine the fMRI neuroimaging data, which will enable us to demonstrate eTNS’ mechanism of action and the physiology of response.”

“We are proud to support our world-class academic sponsors during the conduct of these important clinical trials,” added Colin Kealey, M.D., President and Chief Executive Officer of NeuroSigma. “The trials will produce a robust data set encompassing both children and adolescents with ADHD, as well as use of the device as an adjunctive therapy for patients already on medication. We believe this will set the stage for expanding our label into the adolescent and adjunctive populations, thereby adding tremendous value to the company.”

For Patients and Caregivers Interested in the Trials
If you are interested in learning more about how you or your loved ones can participate in these trials, please visit the websites below:

UCLA & Seattle Children’s Hospital

King’s College and University of Southampton

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine